{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-118573","form_type":"8-K","ticker":"ZBH","cik":"0001136869","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.764366+00:00","generated_at":"2026-05-30T08:00:56.849738+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Zimmer Biomet Q3 sales up 4.1% cc; lowers FY2024 guidance","bullets":["Q3 net sales $1.824B (+4.1% cc); diluted EPS $1.23, adjusted EPS $1.74.","FY2024 constant currency revenue growth guidance narrowed to 4.25%-4.75% from 5.0%-6.0%.","FY2024 adjusted diluted EPS guidance lowered to $7.95-$8.05 from $8.00-$8.15.","CEO Ivan Tornos cited ERP implementation challenges as headwind to full-year performance.","Completed acquisition of OrthoGrid Systems (AI hip guidance); launched Z1 Femoral Hip System."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-118573","json":"https://secwatch.observer/filing/0000950170-24-118573.json","markdown":"https://secwatch.observer/filing/0000950170-24-118573.md","text":"https://secwatch.observer/filing/0000950170-24-118573.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024118573/0000950170-24-118573-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024118573/zbh-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:00:56.849738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}